0001493152-26-022722
SEC filingRevenue more than doubled year-over-year to $1.1M from research collaborations, narrowing operating and net losses through higher top-line contributions and reduced R&D spend amid commercialization progress.
Net loss improved 3.6% to $2.0 million, with diluted EPS at -$0.05 versus -$0.07 year-over-year, as revenue growth enhanced loss absorption despite higher other expenses from reduced interest income. Operating margin stood at -171.3%, underscoring the early-stage nature of biotech platform investments where costs exceed topline amid R&D-to-commercial transition.
Operationally, Dyadic advanced commercialization with Fermbox Bio, completing production validation and launching RNase-free DNase I as their first joint product. Scale-up continues for transferrin and other recombinant proteins and enzymes to enable market launches and channel expansion. In life sciences, Proliant Health's February 2026 launch of AlbuFree™ DX recombinant human albumin—produced using the Dapibus™ platform—marks a key milestone, reducing regulatory hurdles compared to therapeutics and positioning Dyadic for profit shares and royalties.
Cash from operations was -$1.96 million, comparable to the prior period's -$1.95 million, signaling steady burn to fund platform validation and partnerships. Management's going concern evaluation considers plans like Convertible Notes maturing in 2027 and the ATM program to mitigate liquidity risks. Investors should track product sales ramp, grant execution, and Nasdaq compliance by June 2026, as these will determine sustained revenue diversification and path to profitability in applied biomanufacturing.